11450 Federal Register / Vol. 87, No. 40 / Tuesday, March 1, 2022 / Notices 

(CCDBG Act), as amended, CCDBG Act 

of 2014 (Pub. L. 113–186), and 42 U.S.C. 

9858. The Plan, submitted on the ACF– 

118A, is required triennially, and 

remains in effect for 3 years. The Plan 

provides ACF and the public with a 

description of and assurance about the 

tribes’ child care programs. These Plans 

are the applications for CCDF funds. 

The Office of Child Care has given 

thoughtful consideration of any 

comments received on the Plan Preprint 

document and revised the document in 

line with comments. Additionally, 

based on responses from Tribes and the 

current context of managing the COVID– 

19 Pandemic, OCC will postpone 

modernizing the allocation size 

thresholds. Requirements for this Tribal 

CCDF Plan submission will continue to 

be based on FY 2016 allocations. 

Consistent with the statute and 

regulations, ACF requests revision of the 

ACF–118A with minor modifications. 

This 30-day second Public Comment 

Period provides an opportunity for the 

public to submit comments to OMB. 

Respondents: Tribal CCDF lead 

agencies. 

ANNUAL BURDEN ESTIMATES

Instrument 

Total 

number of 

respondents 

Total 

number of 

responses per 

respondent 

Average 

burden hours 

per response 

Total 

burden hours 

Annual 

burden hours 

ACF–118A Part I (for all tribes) ........................................... 265 1 120 31,800 10,600 

ACF–118A Part II (for medium and large tribes only) ......... 106 1 24 2,544 848 

Estimated Total Annual Burden 

Hours: 11,448. 

Authority: Pub. L. 113–186) and 42 

U.S.C. 9858c. 

Mary B. Jones, 

ACF/OPRE Certifying Officer. 

[FR Doc. 2022–04199 Filed 2–28–22; 8:45 am] 

BILLING CODE 4184–43–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Agency Information Collection 

Activities: Proposed Collection: Public 

Comment Request Environmental 

Information and Documentation, OMB 

No. 0915–0324—Extension 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services. 

ACTION: Notice. 

SUMMARY: In compliance with the 

requirement for opportunity for public 

comment on proposed data collection 

projects of the Paperwork Reduction Act 

of 1995, HRSA announces plans to 

submit an Information Collection 

Request (ICR), described below, to the 

Office of Management and Budget 

(OMB). Prior to submitting the ICR to 

OMB, HRSA seeks comments from the 

public regarding the burden estimate, 

below, or any other aspect of the ICR. 

DATES: Comments on this ICR should be 

received no later than March 31, 2022. 

ADDRESSES: Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under Review—Open for 

Public Comments’’ or by using the 

search function. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the data collection plans and draft 

instruments, email paperwork@hrsa.gov 

or call Samantha Miller, the acting 

HRSA Information Collection Clearance 

Officer at (301) 443–9094. 

SUPPLEMENTARY INFORMATION: When 

submitting comments or requesting 

information, please include the 

information collection request title for 

reference. 

Information Collection Request Title: 

Environmental Information and 

Documentation (EID) OMB No. 0915– 

0324—Extension. 

Abstract: HRSA is requesting 

extension of the approval for the EID 

checklist which consists of information 

that the agency is required to obtain to 

comply with the National 

Environmental Policy Act of 1969 

(NEPA). NEPA establishes the federal 

government’s national policy for 

protection of the environment. HRSA 

has developed the EID for applicants of 

funding that would potentially impact 

the environment and to ensure that their 

decision-making processes are 

consistent with NEPA. 

A 60-day notice published in the 

Federal Register, 86 FR 69655 

(December, 8, 2021). There were no 

public comments. 

Need and Proposed Use of the 

Information: Applicants must provide 

information and assurance of 

compliance with NEPA on the EID 

checklist. This information is reviewed 

in the Pre-Award stage (and/or prior to 

the implementation of the project). The 

information is reviewed in the PostAward stage for project changes and the 

information is reviewed before the 

implementation of the project changes. 

Likely Respondents: HRSA applicants 

applying for federal loan guarantees, 

federal construction grants, and 

cooperative agreements. 

Burden Statement: Burden in this 

context means the time expended by 

persons to generate, maintain, retain, 

disclose, or provide the information 

requested. This includes the time 

needed to review instructions; to 

develop, acquire, install, and utilize 

technology and systems for the purpose 

of collecting, validating and verifying 

information, processing and 

maintaining information, and disclosing 

and providing information; to train 

personnel and to be able to respond to 

a collection of information; to search 

data sources; to complete and review 

the collection of information; and to 

transmit or otherwise disclose the 

information. The total annual burden 

hours estimated for this ICR are 

summarized in the table below. 


jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 40 / Tuesday, March 1, 2022 / Notices 11451 

TOTAL ESTIMATED ANNUALIZED BURDEN HOURS

Form name Number of 

respondents 

Number of 

responses per 

respondent 

Total 

responses 

Average 

burden per 

response 

(in hours) 

Total burden 

hours 

NEPA EID Checklist ............................................................ 1,500 1 1,500 1 1,500 

Total .............................................................................. 1,500 ........................ 1,500 ........................ 1,500 

HRSA specifically requests comments 

on (1) the necessity and utility of the 

proposed information collection for the 

proper performance of the agency’s 

functions, (2) the accuracy of the 

estimated burden, (3) ways to enhance 

the quality, utility, and clarity of the 

information to be collected, and (4) the 

use of automated collection techniques 

or other forms of information 

technology to minimize the information 

collection burden. 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2022–04267 Filed 2–28–22; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: Development and 

Commercialization of Chimeric Antigen 

Receptor T-Cell Therapies (CAR–T) 

That are Specific to CD22 and Other BCell Antigens for the Treatment of BCell Malignancies 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Cancer Institute, 

an institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an Exclusive Patent License to 

practice the inventions embodied in the 

Patents and Patent Applications listed 

in the Supplementary Information 

section of this Notice to Syncopation 

Life Sciences Inc., (‘‘Syncopation’’), 

located in Palo Alto, California. 

DATES: Only written comments and/or 

complete applications for a license 

which are received by the National 

Cancer Institute’s Technology Transfer 

Center on or before March 16, 2022 will 

be considered. 

ADDRESSES: Requests for copies of the 

patent applications, inquiries, and 

comments relating to the contemplated 

Exclusive Patent License should be 

directed to: Jim Knabb, Senior 

Technology Transfer Manager, at 

Telephone: (240)–276–7856; or at email: 

jim.knabb@nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

E–080–2012–0: Human Monoclonal 

Antibodies Specific for CD22 

1. US Provisional Patent Application 

61/042,329, filed April 4, 2008 (E–080– 

2008–0–US–01); 

2. International Patent Application 

PCT/US2009/039,080, Filed April 1, 

2009 (E–080–2008/0–PCT–02); 

3. US Patent Application: 12/934,214, 

filed September 23, 2010 (E–080–2008– 

0–US–03); 

4. US Patent Application 13/959,061, 

filed August 5, 2015 (E–080–2008–0– 

US–04); 

5. US Patent Application 15/012,023, 

filed February 1, 2016 (E–080–2008–0– 

US–05); 

6. US Patent Application 15/424,238, 

filed February 3, 2017 (E–080–2008–0– 

US–06). 

E–291–2012–0: M971 Chimeric Antigen 

Receptors 

1. US Provisional Patent Application 

61/717,960, filed October 24, 2012 (E– 

291–2012–0–US–01); 

2. International Patent Application 

PCT/US2013/060332, filed September 

18, 2013 (E–291–2012–0–PCT–02); 

3. Australia Application No: 

2019235926, filed September 2, 2020 

(E–291–2012–0–AU–03); 

4. Brazil Patent Application 

BR112015009003–6, filed April 22, 2015 

(E–291–2012–0–BR–04); 

5. Canada Application No: 2889055, 

filed September 18, 2013 (E–291–2012– 

0–CA–05); 

6. China Application No: 

201380061387.5, filed May 25, 2015 (E– 

291–2012–0–CN–06); 

7. European Patent Application No: 

13773468.7, filed September 18, 2013 

(E–291–2012–0–EP–07); 

8. India Patent Application No: 2344/ 

CHENP/2015, filed September 18, 2013 

(E–291–2012–0–IN–08); 

9. Japan Application No: 539602/ 

2015, filed April 24, 2015 (E–291–2012– 

0–JP–09); 

10. Russia Patent Application: 

2015117237, filed May 7, 2015 (E–291– 

2012–0–RU–10); 

11. US Patent Application: 14/ 

437,889, filed April 23, 2015 (E–291– 

2012–0–US–11); 

12. Hong Kong Patent Application: 

16101891.0, filed February 19, 2016 (E– 

291–2012–0–HK–12); 

13. Russia Patent Application: 

2018116582, filed May 4, 2018 (E–291– 

2012–0–RU–13); 

14. Japan Patent Application: 2018– 

088908, filed May 2, 2018, (E–291– 

2012–0–JP–14); 

15. Australia Patent Application: 

2018204257, filed June 14, 2018 (E– 

291–2012–0–AU–16); 

16. US Patent Application: 16/ 

107,271, filed August 21, 2018 (E–291– 

2012–0–US–17); 

17. Germany Patent Application: 

13773468.7, filed April 22, 2015 (E– 

291–2012–0–DE–18); 

18. Spain Patent Application: 

13773468.7, filed April 22, 2015 (E– 

291–2012–0–ES–19); 

19. France Patent Application: 

13773468.7, filed April 22, 2015 (E– 

291–2012–0–FR–20); 

20. Great Britain Patent Application: 

13773468.7, filed April 22, 2015 (E– 

291–2012–0–GB–21); 

21. Italy Patent Application: 

13773468.7, filed April 22, 2015 (E– 

291–2012–0–IT–22); 

22. China Patent Application: 

201910500128.7, filed June 11, 2019 (E– 

291–2012–0–CN–23); 

23. US Patent Application: 16/ 

869,792, filed May 8, 2020 (E–291– 

2012–0–US–24). 

E–017–2017–0: CD19/CD22 Bicistronic 

CAR Targeting Human B-Cell 

Malignancies 

1. US Provisional Patent Application 

No.: 62/135,442, filed May 15, 2017 (E– 

017–2017–0–US–01); 

2. International Patent Application 

PCT/US2018/032,809, filed May 15, 

2018 (E–017–2017–0–PCT–02); 

3. Australia Patent Application No.: 

2018269194, filed October 28, 2019 (E– 

017–2017–0–AU–03); 

4. Canada Patent Application No: 

3062433, filed May 15, 2018 (E–017– 

2017–0–CA–04); 


jspears on DSK121TN23PROD with NOTICES1